Mabpharm Limited (2181.HK)

HKD 0.48

(-3.03%)

Operating Expenses Summary of Mabpharm Limited

Mabpharm Limited's latest annual operating expenses in 2023 was 75.23 Million CNY , up 14.08% from previous year.
Mabpharm Limited's latest quarterly operating expenses in 2024 Q2 was 93.65 Million CNY , down 0.0% from previous quarter.
Mabpharm Limited reported a annual operating expenses of 239.75 Million CNY in annual operating expenses 2022, down -31.65% from previous year.
Mabpharm Limited reported a annual operating expenses of 350.76 Million CNY in annual operating expenses 2021, up 114.62% from previous year.
Mabpharm Limited reported a quarterly operating expenses of 93.65 Million CNY for 2024 Q1, up 31.11% from previous quarter.
Mabpharm Limited reported a quarterly operating expenses of 66.67 Million CNY for 2023 Q2, down 0.0% from previous quarter.

Annual Operating Expenses Chart of Mabpharm Limited (2023 - 2017)

Historical Annual Operating Expenses of Mabpharm Limited (2023 - 2017)

Year	Operating Expenses	Operating Expenses Growth
2023	75.23 Million CNY	14.08%
2022	239.75 Million CNY	-31.65%
2021	350.76 Million CNY	114.62%
2020	163.43 Million CNY	-22.39%
2019	210.59 Million CNY	42.73%
2018	147.54 Million CNY	247.36%
2017	42.47 Million CNY	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q2	93.65 Million CNY	0.0%
2024 Q1	93.65 Million CNY	31.11%
2023 Q2	66.67 Million CNY	0.0%
2023 Q1	66.67 Million CNY	18.2%
2023 FY	273.52 Million CNY	14.08%
2023 Q4	71.42 Million CNY	0.73%
2023 Q3	70.91 Million CNY	6.36%
2022 Q4	56.4 Million CNY	0.0%
2022 Q2	65.87 Million CNY	0.0%
2022 Q1	65.87 Million CNY	-10.98%
2022 Q3	56.4 Million CNY	-14.37%
2022 FY	239.75 Million CNY	-31.65%
2021 Q4	73.99 Million CNY	0.0%
2021 Q1	104.7 Million CNY	60.58%
2021 Q2	104.7 Million CNY	0.0%
2021 Q3	73.99 Million CNY	-29.33%
2021 FY	350.76 Million CNY	114.62%
2020 Q4	65.2 Million CNY	0.0%
2020 Q3	65.2 Million CNY	118.31%
2020 FY	163.43 Million CNY	-22.39%
2020 Q2	29.86 Million CNY	0.0%
2020 Q1	29.86 Million CNY	-38.67%
2019 Q1	57.71 Million CNY	-4.42%
2019 FY	210.59 Million CNY	42.73%
2019 Q3	48.69 Million CNY	-15.62%
2019 Q2	57.71 Million CNY	0.0%
2019 Q4	48.69 Million CNY	0.0%
2018 Q2	25.69 Million CNY	0.0%
2018 Q3	60.38 Million CNY	135.0%
2018 Q4	60.38 Million CNY	0.0%
2018 Q1	25.69 Million CNY	183.41%
2018 FY	147.54 Million CNY	247.36%
2017 Q1	-6.93 Million CNY	0.0%
2017 FY	42.47 Million CNY	0.0%
2017 Q4	-30.8 Million CNY	0.0%
2017 Q2	-6.93 Million CNY	0.0%
2016 Q4	-6.93 Million CNY	0.0%

Peer Operating Expenses Comparison of Mabpharm Limited

Name	Operating Expenses	Operating Expenses Difference
Uni-Bio Science Group Limited	325.05 Million HKD	76.853%
CK Life Sciences Int'l., (Holdings) Inc.	739.25 Million HKD	89.822%